Related Experiment Video

Updated: May 25, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Mineralocorticoid receptor blockade in chronic kidney disease

Andrew S Bomback1, Philip J Klemmer

  • 1Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.

Blood Purification
|January 25, 2012
PubMed

Insights

Mineralocorticoid receptor blockers (MRBs) show promise for chronic kidney disease (CKD) treatment. Low-dose MRBs may provide unique benefits, despite hyperkalemia concerns in CKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Mineralocorticoid receptor blockers (MRBs) are established treatments for heart failure and hypertension.
  • Their application in chronic kidney disease (CKD) is limited by hyperkalemia risks and assumptions about existing therapies.
  • Aldosterone activity may remain high in some CKD patients despite conventional treatment.

Purpose of the Study:

  • To evaluate the potential benefits of mineralocorticoid receptor blockers (MRBs) in chronic kidney disease (CKD) populations.
  • To address concerns regarding hyperkalemia and explore the efficacy of low-dose MRB therapy in CKD.

Main Methods:

  • Review of existing literature on MRB use in cardiovascular and renal diseases.
  • Analysis of potential mechanisms for MRB action in CKD.
  • Consideration of patient selection for MRB therapy in CKD.

Main Results:

  • MRBs are effective in heart failure and resistant hypertension.
  • Hyperkalemia is a significant concern for MRB use in CKD.
  • Low-dose MRBs might offer specific antihypertensive and anti-inflammatory effects in certain CKD patients.

Conclusions:

  • Mineralocorticoid receptor blockers (MRBs) hold potential for select chronic kidney disease (CKD) patients.
  • Careful patient selection and low-dose initiation may mitigate risks like hyperkalemia.
  • Further research is warranted to define the role of MRBs in managing CKD.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...